Comorbid Latent Adrenal Insufficiency with XXXX .

@entity1 @entity1669 @entity344 @entity4053 @entity5343 @entity701 @entity85
BACKGROUND: @entity1669 ( @entity1669 ) has been occasionally observed in @entity1 with @entity5343 ( @entity5343 ). In contrast, less than 20 cases of comorbid @entity5343 with @entity1669 have been found in the English literature. One conceivable reason is difficulty in detecting latent @entity5343 . OBJECTIVE: Information of clinical presentation and diagnostics is sought to facilitate diagnosis of latent @entity5343 . METHODS: Latent @entity5343 was pursued in 11 @entity1 among 159 @entity1669 @entity1 . All of them were maintained in a euthyroid state. Except for one @entity1 with @entity85 , the other @entity1 , who were asymptomatic in their daily lives, presented with recurrent nonspecific @entity344 or fatigue in stress-associated circumstances. Morning @entity701 level <303 nmol/l was used as an inclusion criterion. Their basal adrenocorticotropic hormone levels were normal. The adrenal status was examined by a provocation test, either an insulin-induced @entity4053 test or a 1- g intravenous corticotrophin test. Eleven @entity1 showed subnormal @entity701 response. They were supplemented with @entity701 of doses  <=15 mg/day. After a few months of supplementation, @entity5343 was confirmed by another provocation test. Three @entity1 were excluded because of dissociation of two provocation tests. RESULTS: Comorbid latent @entity5343 with @entity1669 was pursued from the symptoms stated above and proven by two provocation tests; it was found in 5% (8/159) of the @entity1 . CONCLUSION: When @entity1 with @entity1669 are troubled by recurrent stress-associated gastrointestinal or constitutional symptoms or @entity85 which have remained unrelieved by adjustment of thyroid medication, these symptoms may be a manifestation of comorbid latent @entity5343 . It is worth investigating such @entity1 for latent @entity5343 .
